Floatz logo

cg-0255 besylate for

Acute Coronary Syndromes (ACS)

Shanghai CureGene Pharmaceutical Co., Ltd.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Acute Coronary Syndromes (ACS) cohort.

Asset / SponsorPhaseRating
Acetylsalicylic Acid
Shanghai CureGene Pharmaceutical Co., Ltd.
Phase 4BBB
Lipitor
Punjab Institute of Cardology
Phase 4BB
Plavix
Shanghai CureGene Pharmaceutical Co., Ltd.
Phase 4BB
Ticagrelor
Tianjin Institute of Pharmaceutical Research Co., Ltd
Phase 4BB
Exenatide
Saint Luke's Health System
Phase 4BB

View all 34 →

Same molecule, other indications

cg-0255 besylate for is also rated in:

myocardial infarctionDormant
CC
Indicative ·
43 / 100
View asset →
stroke disorderDormant
CC
Indicative ·
43 / 100
View asset →
peripheral arterial diseaseDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →